Women’s health

DDW’s Diana Spencer speaks to Alok Javali, CSO of dawn-bio, a new addition to BioInnovation Institute’s (BII) Venture Lab acceleration programme, about the lack of innovation in women’s reproductive health and the company’s plans to fill the vacuum. Earlier this year, dawn-bio was one of five drug discovery companies to enter the BioInnovation Institute’s (BII) […]

PrecisionLife and the University of Oxford have signed a data access agreement to license the Oxford Endometriosis Gene (OXEGENE) dataset to develop new personalised treatments for endometriosis patients. Endometriosis affects 10% of women globally, but on average it takes over seven years for patients to receive a diagnosis. There are currently no approved diagnostic biomarkers […]

The International Day of Action for Women’s Health has been celebrated on 28 May every year since 1987. In 2023, DDW’s Megan Thomas looks at how the drug discovery industry is taking action in this arm of healthcare.  Context A 2023 McKinsey study revealed that despite the exponential growth in data generated across the healthcare […]

The AACR has announced a new funding opportunity in collaboration with Victoria’s Secret and Pelotonia.  The fund is for female investigators researching breast and gynaecologic cancers that focus on prevention, detection, diagnostic, and treatment innovations for breast and gynaecologic cancers and advancing outcomes for cancer health disparities.  The application deadline is June 7.  The Victoria’s […]

BioInnovation Institute Foundation (BII) and Ferring Pharmaceuticals have expanded their collaboration with the objective to accelerate world-class life science innovation within women’s health. New activities will include supporting BII to source and potentially fund and incubate early-stage start-ups and projects within the field of reproductive medicine. “The new strategic collaboration, highlights Ferring’s continued commitment to […]

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending Ryeqo (relugolix 40mg, estradiol 1mg, and norethisterone acetate 0.5mg), for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.  The decision makes the relugolix combination therapy the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist […]

Life science company ValiRx has appointed Dr Cathy Tralau-Stewart as its interim Chief Scientific Officer (CSO) to help bolster its drug discovery and therapeutic expertise. Dr Tralau-Stewart has over 20 years’ senior academic and industry leadership experience and joins ValiRx from drug discovery company C4X Discovery. At C4X Discovery Dr Tralau-Stewart was CSO and managed […]